Dyslipidemia in Patients with Psoriasis and Psoriatic Arthritis

Background: Different comorbidities, including metabolic syndrome, altered lipid profile, and an increased cardiovascular risk commonly associated with Psoriasis and psoriatic arthritis (PsA). This study aimed to declare the correlation between dyslipidemia and Psoriasis. Patents and methods: Ninety-tow patients (29 patients with PSA and 63 patients with psoriasis vulgaris) and 88 healthy, age and sex-matched controls were recruited for the study. Serum levels of total cholesterol (TC), triglycerides (TG), high-density lipoproteins (HDL), and low-density lipoproteins (LDL) were measured. The severity of Psoriasis and PsA activity was assessed using the Psoriasis Area and Severity Index (PASI) and the Disease Activity Score using 28 joints (DAS28) for patients with Psoriasis and PSA, respectively. Results: HDL level was significantly lower in the patients than in controls. TC, TG, and LDL levels were significantly higher in the patient group than those in the control group. There are no significant differences in serum TC, TG, LDL, and HDL levels in Psoriasis and psoriatic arthritis. The serum TC, TG, LDL, and HDL levels were not related to disease duration but were associated with high disease activity. Conclusion: Dyslipidemia was found in a high percentage of psoriatic and PsA patients than in healthy controls. Dyslipidemia was associated with high disease activity in psoriatic and PsA patients. As Psoriasis and PsA are associated with an increased risk of cardiovascular diseases, thorough lipid levels estimation is required.